HIV vaccine vCP1521 / Sanofi - LARVOL DELTA

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Active, not recruiting; Sponsor: U.S. Army Medical Research and Development Command; Trial completion date: May 2021 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Recruiting; Sponsor: U.S. Army Medical Research and Materiel Command; Not yet recruiting ➔ Recruiting; Trial primary completion date: Aug 2015 ➔ Nov 2016

Clinical • Enrollment open • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Active, not recruiting; Sponsor: U.S. Army Medical Research and Materiel Command; Suspended ➔ Active, not recruiting

Clinical • Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Suspended; Sponsor: U.S. Army Medical Research and Materiel Command; Recruiting ➔ Suspended

Clinical • Trial suspension • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Active, not recruiting; Sponsor: U.S. Army Medical Research and Development Command; Trial completion date: Dec 2019 ➔ May 2020; Trial primary completion date: Jul 2019 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Active, not recruiting; Sponsor: U.S. Army Medical Research and Development Command; Trial completion date: May 2020 ➔ May 2021; Trial primary completion date: Dec 2019 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Not yet recruiting; Sponsor: U.S. Army Medical Research and Materiel Command

Clinical • New P2 trial • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Active, not recruiting; Sponsor: U.S. Army Medical Research and Materiel Command; Trial primary completion date: Nov 2017 ➔ Mar 2018

Clinical • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Active, not recruiting; Sponsor: U.S. Army Medical Research and Materiel Command; Trial primary completion date: Nov 2016 ➔ Nov 2017

Clinical • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • IFNG

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E (clinicaltrials.gov) - P2; N=360; Active, not recruiting; Sponsor: U.S. Army Medical Research and Materiel Command; Trial completion date: Apr 2018 ➔ Oct 2018; Trial primary completion date: Mar 2018 ➔ Sep 2018

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • IFNG

Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144 (clinicaltrials.gov) - P2; N=162; Active, not recruiting; Sponsor: U.S. Army Medical Research and Development Command; Trial completion date: Dec 2020 ➔ Jul 2021; Trial primary completion date: Jul 2020 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • IFNG

New Vaccines in the Pipeline 2020 (Pharmacy Times) - "The vaccine furthest along is ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59.35 This vaccine is a recombinant protein that contains genes from HIV as well as MF59...The trial with this vaccine—currently taking place in Mozambique, South Africa, and Zimbabwe—is scheduled to be completed in August 2021."

Trial completion date • Trial status • Human Immunodeficiency Virus

Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. (PubMed, Lancet HIV) - P2 | "Taken together, these results suggest that additional boosting of the RV144 regimen with longer intervals between the primary vaccination series and late boost improved immune responses and might improve the efficacy of preventing HIV acquisition."

Clinical • Journal • Allergy • Human Immunodeficiency Virus • Immunology • Infectious Disease

Simplified steps to heterologous prime-boost HIV vaccine development? (PubMed, J Clin Invest) - "The RV 144 HIV vaccine efficacy study showed a reduction in HIV-1 infection risk in Thai volunteers who received two priming vaccinations of vCP1521 ALVAC (attenuated recombinant canarypox virus expressing HIV group-specific antigen, polymerase, and envelope genes) followed by two additional ALVAC vaccinations and coadministration of purified bivalent gp120 proteins (AIDSVAX B/E)...build on these results by substituting a DNA plasmid cocktail expressing HIV-1 subtype C group-specific antigen, polymerase, and envelope antigen genes (DNA-HIV-PT123) for ALVAC in a phase 1b safety and immunogenicity study. The results indicate that the vaccine regimen is safe, elicits promising cross-subtype humoral and cellular responses, and opens up potentially simplified approaches to HIV-1 vaccine development."

Journal • Gene Therapies • Immunology • Infectious Disease